ER/PR+ 和 HER2- 乳腺癌患者扩展 Cox 预后模型的建立与验证:一项回顾性队列研究。
Development and validation of an extended Cox prognostic model for patients with ER/PR+ and HER2- breast cancer: a retrospective cohort study.
机构信息
Department of Breast Surgery, Huangpu Branch of Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200011, China.
Department of General Surgery, Changhai Hospital, Naval Medical University (Second Military Medical University), Shanghai, 200433, China.
出版信息
World J Surg Oncol. 2022 Oct 12;20(1):338. doi: 10.1186/s12957-022-02790-0.
BACKGROUND
The purpose of this study was to explore a new estrogen receptor (ER) and/or progesterone receptor (PR)+ and human epidermal growth factor receptor 2 (HER2)- breast cancer prognostic model, called the extended Cox prognostic model, for determining the cutoff values for multiple continuous prognostic factors and their interaction via the new model concept and variable selection method.
METHODS
A total of 335 patients with ER/PR+ and HER2- breast cancer were enrolled for the final analysis. The primary endpoint was breast cancer-specific mortality (BCSM). Prognostic factors (histological grade, histological type, stage, T, N, lymphovascular invasion (LVI), P53, Ki67, ER, PR, and age) were included in this study. The four continuous variables (Ki67, ER, PR, and age) were partitioned into a series of binary variables that were fitted in the multivariate Cox analysis. A smoothly clipped absolute deviation (SCAD) variable selection method was used. Model performance was expressed in discrimination and calibration.
RESULTS
We developed an extended Cox model with a time threshold of 164-week (more than 3 years) postoperation and developed a user-friendly nomogram based on our extended Cox model to facilitate clinical application. We found that the cutoff values for PR, Ki67, and age were 20%, 60%, and 41-55 years, respectively. There was an interaction between age and PR for patients aged ≥ 41 years and PR ≥ 20% at 164-week postoperation: the older the patients with ER/PR+, HER2-, and PR ≥ 20% were, the lower the survival and more likely to recur and metastasize exceeding 164 weeks (more than 3 years) after surgery.
CONCLUSIONS
Our study offers guidance on the prognosis of patients with ER/PR+ and HER2- breast cancer in China. The new concept can inform modeling and the determination of cutoff values of prognostic factors in the future.
背景
本研究旨在探索一种新的雌激素受体(ER)和/或孕激素受体(PR)+和人表皮生长因子受体 2(HER2)-乳腺癌预后模型,称为扩展 Cox 预后模型,通过新模型概念和变量选择方法确定多个连续预后因素及其相互作用的截止值。
方法
共纳入 335 例 ER/PR+和 HER2-乳腺癌患者进行最终分析。主要终点是乳腺癌特异性死亡率(BCSM)。预后因素(组织学分级、组织学类型、分期、T、N、淋巴血管侵犯(LVI)、P53、Ki67、ER、PR 和年龄)纳入本研究。将四个连续变量(Ki67、ER、PR 和年龄)分为一系列二进制变量,在多变量 Cox 分析中进行拟合。使用光滑裁剪绝对偏差(SCAD)变量选择方法。模型性能通过区分度和校准度来表示。
结果
我们建立了一个具有 164 周(超过 3 年)术后时间阈值的扩展 Cox 模型,并基于我们的扩展 Cox 模型开发了一个易于使用的列线图,以方便临床应用。我们发现 PR、Ki67 和年龄的截止值分别为 20%、60%和 41-55 岁。在年龄≥41 岁和 PR≥20%的患者中,年龄和 PR 之间存在交互作用:年龄较大且 ER/PR+、HER2-和 PR≥20%的患者,生存时间越短,术后超过 164 周(超过 3 年)复发和转移的可能性越大。
结论
本研究为中国 ER/PR+和 HER2-乳腺癌患者的预后提供了指导。新概念可以为未来的建模和预后因素截止值的确定提供信息。